Kinespir Patch (Diclofenac Sodium)

Diclofenac sodium reduces pain and inflammation by reversibly inhibiting the cyclooxygenase‑1 (COX‑1) and cyclooxygenase‑2 (COX‑2) enzymes. This blocks the conversion of arachidonic acid into prostaglandins, which are key mediators of inflammation, fever and pain. When delivered via a transdermal patch, the drug concentrates in the underlying tissues, achieving local action.

The specific dosing regimen for Kinespir Patch is determined by the prescribing healthcare professional based on the patient’s condition, severity of symptoms and treatment response. The prescriber will select the appropriate patch size, frequency of change and duration of therapy in accordance with the product’s labeling and clinical guidelines.

Safety data for diclofenac sodium in pregnancy and lactation are limited. The product should be used only if the potential benefit justifies any possible risk to the fetus or infant, and it is generally avoided during the third trimester. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their physician.

To request Kinespir Patch, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both formulations contain the same active ingredient, but the transdermal patch delivers diclofenac directly to the skin and underlying tissues, offering localized relief with lower systemic drug levels. Oral tablets provide systemic exposure, which may be useful for widespread pain but carry higher risk of gastrointestinal, renal and cardiovascular adverse effects.

Store the patches at room temperature, ideally below 25 °C, in their original sealed packaging. Protect them from moisture, direct sunlight and excessive heat. Do not expose the patches to temperatures above the recommended range, and keep them out of reach of children.

Clean and dry the intended skin area before application. Remove the protective liner and press the adhesive side of the patch firmly onto the skin, smoothing out any air bubbles. The patch should remain in place for the duration prescribed, after which it is removed and disposed of according to local regulations.

Although rare, serious adverse reactions can include severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, systemic gastrointestinal bleeding or ulceration, and renal or hepatic impairment. Patients should seek immediate medical attention if they develop widespread rash, blistering, blood in stool or urine, or signs of kidney or liver dysfunction.

Kinespir Patch is contraindicated in individuals with known hypersensitivity to diclofenac, other NSAIDs, or any component of the patch. It should also be avoided in patients with active gastrointestinal ulceration, severe renal or hepatic disease, uncontrolled hypertension, or those receiving anticoagulant therapy without close monitoring.